Title |
Pathophysiology and Clinical Utility of Non-coding RNAs in Epilepsy
|
---|---|
Published in |
Frontiers in Molecular Neuroscience, August 2017
|
DOI | 10.3389/fnmol.2017.00249 |
Pubmed ID | |
Authors |
Yiye Shao, Yinghui Chen |
Abstract |
Epilepsy is a common neurologic disorder. The underlying pathological processes include synaptic strength, inflammation, ion channels, and apoptosis. Acting as epigenetic factors, non-coding RNAs (ncRNAs) participate in the regulation of pathophysiologic processes of epilepsy and are dysregulated during epileptogenesis. Aberrant expression of ncRNAs are observed in epilepsy patients and animal models of epilepsy. Furthermore, ncRNAs might also be used as biomarkers for diagnosis and the prognosis of treatment response in epilepsy. In this review, we will summarize the role of ncRNAs in the pathophysiology of epilepsy and the putative utilization of ncRNAs as diagnostic biomarkers and therapeutic targets. |
X Demographics
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 2 | 67% |
Unknown | 1 | 33% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 2 | 67% |
Practitioners (doctors, other healthcare professionals) | 1 | 33% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 57 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 9 | 16% |
Student > Ph. D. Student | 8 | 14% |
Researcher | 7 | 12% |
Other | 5 | 9% |
Student > Master | 4 | 7% |
Other | 7 | 12% |
Unknown | 17 | 30% |
Readers by discipline | Count | As % |
---|---|---|
Biochemistry, Genetics and Molecular Biology | 11 | 19% |
Medicine and Dentistry | 8 | 14% |
Neuroscience | 6 | 11% |
Agricultural and Biological Sciences | 5 | 9% |
Pharmacology, Toxicology and Pharmaceutical Science | 3 | 5% |
Other | 6 | 11% |
Unknown | 18 | 32% |